Med-X

Med-X Partners with Anasac Ambiental for Nature-Cide Product Distribution in South America

Exclusive Distributor to Drive International Growth in Chile, Argentina, Peru and Colombia

LOS ANGELES – January 9, 2025 -- Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, today announced an international distribution agreement with Anasac Ambiental S.A., providing exclusive Nature-Cide distribution rights in Chile, Argentina, Peru and Colombia.

Anasac, a Chilean company, has provided sustainable and innovative solutions that promote development and wellbeing in areas including crop protection, seeds, veterinary care, home & garden, environmental health, pets, hygiene & disinfection, and medication for over 75 years. Anasac has a presence in 19 counties worldwide with over 1,500 products. The company’s subsidiary, Anasac Ambiental, produces and markets solutions for pets, gardens and green areas, as well as urban and agro-industrial pest control.

Per the terms of the agreement, Anasac Ambiental will serve as the exclusive distributor of the Nature-Cide portfolio of indoor and outdoor pest control solutions to a wide variety of professional pest management customers in Chile, Argentina, Peru and Colombia.

Matthew Mills, Chief Executive Officer of Med-X, commented: "This new international distribution agreement marks our entrance into the South American market with Anasac, a well-known Chilean leader in agriculture and pest control. Anasac Ambiental will help to introduce our flagship Nature-Cide product portfolio into Chile and neighboring countries Argentina, Peru and Colombia.

“As a major agricultural region with significant pest pressure, the need for Nature-Cide in home, agricultural and commercial applications has never been stronger. We look forward to working closely with the Anasac team to provide the Nature-Cide product portfolio as a best-in-class option to pest control operators seeking sustainable natural and effective solutions in these exciting new international markets," concluded Mills.

Francisco Di Silvestre, General Manager of Anasac Ambiental, added: “We chose to partner with Med-X due to Nature-Cide's wide range of environmentally friendly and effective solutions, providing critical solutions to the major issues that pest control operators face every day. We believe our base of customers will benefit from these cost-effective high-quality, all-natural products, and improve their pest management programs. At Anasac, we are committed to a sustainable future for pest control and look forward to the opportunity to bring Nature-Cide products to a wide variety of our customers.”

About Med-X, Inc.

Med-X, Inc. is a leading innovator of biological pest control solutions addressing both consumer and professional markets globally. Nature-Cide - the Company's flagship product line - is a safer, all-natural alternative to conventional chemical products, formulated to kill or repel a wide variety of pests. Med-X's comprehensive go-to-market strategy includes leveraging strategic partnerships alongside an integrated e-commerce, brick and mortar and on-site services presence in key markets. For more information, please visit our website at www.medx-rx.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sale of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 of the Securities Act. This press release may contain forward-looking statements regarding projected business performance, operating results, financial condition, and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.

‍

Investor Relations Contact

Lucas Zimmerman

Managing Director

MZ Group - MZ North America

+1 (262) 357-2918

MXRX@mzgroup.us

www.mzgroup.us

‍

FAQs

Why invest in startups?

Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.

How much can I invest?

Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.

How do I calculate my net worth?

To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.

What are the tax implications of an equity crowdfunding investment?

We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.

Who can invest in a Regulation CF Offering?

Individuals over 18 years of age can invest.

What do I need to know about early-stage investing? Are these investments risky?

There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.

When will I get my investment back?

The Common Stock (the "Shares") of Med-X (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.

Can I sell my shares?

Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.

Exceptions to limitations on selling shares during the one-year lockup period:

In the event of death, divorce, or similar circumstance, shares can be transferred to:

• The company that issued the securities

• An accredited investor

• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)

What happens if a company does not reach their funding target?

If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.

How can I learn more about a company's offering?

All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.

What if I change my mind about investing?

You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: investorrelations@medx-rx.com

How do I keep up with how the company is doing?

At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.

Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.

Submission received! Check your inbox for the Med-X updates.

Med-X Partners with Anasac Ambiental for Nature-Cide Product Distribution in South America

NASDAQ Here We Come. Meet MXRX.

Sign Up For Company Updates

FAQs

Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.